Cytokinetics
CYTK
240 hedge funds and large institutions have $3.4B invested in Cytokinetics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 99 increasing their positions, 86 reducing their positions, and 31 closing their positions.
135% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $5.41M
15% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 86
3.62% more ownership
Funds ownership: 108.97% → 112.59% (+3.6%)
4% less funds holding
Funds holding: 250 → 240 (-10)
15% less capital invested
Capital invested by funds: $3.99B → $3.4B (-$595M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.2M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$51.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$50.6M |
| 4 |
HM
HealthCor Management
New York
|
+$37M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$36.3M |
| 2 |
Two Sigma Investments
New York
|
-$17.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$17.4M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$15.6M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$14.3M |
CYTK Hedge Fund Activity: Q1 2022 in Review
240 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2022, worth a combined $3.4B — down 15% from $3.99B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of CYTK and 22 opened new positions — a net loss of 9 holders — while 86 trimmed existing stakes and 99 added.
The largest buyer was Vanguard Group, adding an estimated $62.2M. The largest seller was Wasatch Advisors, cutting an estimated $36.3M.
- 240 institutional investors held Cytokinetics (CYTK) as of Q1 2022, down from 250 in Q4 2021.
- Funds reported $3.4B of Cytokinetics stock for Q1 2022, down 15% quarter-over-quarter.
- 22 funds opened new Cytokinetics positions in Q1 2022 and 31 closed out, a net change of -9 holders.
- The largest Cytokinetics buyer in Q1 2022 was Vanguard Group, an estimated $62.2M added.
- The largest Cytokinetics seller in Q1 2022 was Wasatch Advisors, an estimated $36.3M sold.
Based on aggregated 13F filings for Q1 2022.